FGFR2 Inhibitor Nabs Speedy Approval for Cholangiocarcinoma

(MedPage Today) -- The FDA granted accelerated approval to futibatinib (Lytgobi) tablets for treating adults with intrahepatic cholangiocarcinomas that harbor fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements. Futibatinib...
Source: MedPage Today Public Health - Category: American Health Source Type: news